INTRODUCTION: To determine if amino-terminal propeptide of type 1 procollagen (P1NP) is reliable as a predictor of prostate cancer bone metastases and assess its value as a prognostic indicator of disease progression and survival. MATERIALS AND METHODS: A cohort of patients with prostate cancer between January 1999 and July 2001 were recruited. Prostate-specific antigen (PSA) and P1NP levels were measured. Two years following completion of recruitment, patient notes were reviewed for symptoms of bone metastases and survival. RESULTS: 24 negative and 12 equivocal or positive bone scans were reported for 36 recruited patients. Mean PSA values for patients with negative, equivocal and positive scans were 18.3, 24.9 and 122.5 ng/ml while mean P1NP for the same groups were 38.2, 73.4 and 119.9 ng/ml. For patients with equivocal and positive scan, mean P1NP with and without bone symptoms were 111.5 and 65.7 ng/ml while for surviving and dead patients the values were 63.9 and 120.8 ng/ml, respectively. CONCLUSIONS: Though this study involved a small number of patients, it demonstrates P1NP's potential as a predictor of bone metastases and a prognosticator for disease progression and survival. Copyright (c) 2006 S. Karger AG, Basel.
INTRODUCTION: To determine if amino-terminal propeptide of type 1 procollagen (P1NP) is reliable as a predictor of prostate cancer bone metastases and assess its value as a prognostic indicator of disease progression and survival. MATERIALS AND METHODS: A cohort of patients with prostate cancer between January 1999 and July 2001 were recruited. Prostate-specific antigen (PSA) and P1NP levels were measured. Two years following completion of recruitment, patient notes were reviewed for symptoms of bone metastases and survival. RESULTS: 24 negative and 12 equivocal or positive bone scans were reported for 36 recruited patients. Mean PSA values for patients with negative, equivocal and positive scans were 18.3, 24.9 and 122.5 ng/ml while mean P1NP for the same groups were 38.2, 73.4 and 119.9 ng/ml. For patients with equivocal and positive scan, mean P1NP with and without bone symptoms were 111.5 and 65.7 ng/ml while for surviving and dead patients the values were 63.9 and 120.8 ng/ml, respectively. CONCLUSIONS: Though this study involved a small number of patients, it demonstrates P1NP's potential as a predictor of bone metastases and a prognosticator for disease progression and survival. Copyright (c) 2006 S. Karger AG, Basel.
Authors: Windy Dean-Colomb; Kenneth R Hess; Elliana Young; Terrie G Gornet; Beverly C Handy; Stacy L Moulder; Nuhad Ibrahim; Lajos Pusztai; Daniel Booser; Vicente Valero; Gabriel N Hortobagyi; Francisco J Esteva Journal: Breast Cancer Res Treat Date: 2012-12-15 Impact factor: 4.872
Authors: Robert Coleman; Janet Brown; Evangelos Terpos; Allan Lipton; Matthew R Smith; Richard Cook; Pierre Major Journal: Cancer Treat Rev Date: 2008-06-24 Impact factor: 12.111
Authors: Hawley C Almstedt; Silvie Grote; Joshua R Korte; Stephanie Perez Beaudion; Todd C Shoepe; Sarah Strand; Heather P Tarleton Journal: Bone Rep Date: 2016-09-21